TresibaActive Ingredient(s): Insulin Degludec
FDA Approved: * September 25, 2015
Pharm Company: * NOVO NORDISK INC
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba. It is administered via subcutaneous injection once daily to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin,&... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Tresiba 200 U/Ml Subcutaneous Injection, SolutionNDC: 0169-2550
Tresiba 100 U/Ml Subcutaneous Injection, SolutionNDC: 0169-2660
Tresiba 100 U/Ml Subcutaneous Injection, SolutionNDC: 0169-2662
Tresiba 200 U/Ml Subcutaneous Injection, SolutionNDC: 50090-3491
A-s Medication Solutions
Cost of Tresiba Flextouch
Can anyone tell me what the typical price is for Tresiba Flextouch 200 units/mL?...